Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 04, 2019
TickeronGET DAILY SIGNALS
Bausch Health (BHC, $26.30) beats Q3 revenue expectations; hikes full-year sales guidance

Bausch Health (BHC, $26.30) beats Q3 revenue expectations; hikes full-year sales guidance

Bausch Health posted third-quarter revenue that surpassed analysts’ expectations. The company also boosted its revenue guidance.

In the third quarter, the pharmaceutical company’s revenue increased to $2.21 billion ( from $2.14 billion a year earlier), beating analysts’ estimate of $2.16 billion.

Bausch reported a loss of -$49 million, or -14 cents a share - compared to a loss of -$350 million, or -$1 a share in the year-ago quarter.

Adjusted net income for the quarter came in at $425 million, up from $403 million a year earlier.

Looking ahead, Bausch Health now expects a revenue range of $8.475 billion to $8.625 billion for the full-year 2019, up from its previous guidance of $8.4 billion to $8.6 billion.

CEO Joseph Papa emphasized on the strength of the company's long-standing brands, Xifaxan, BioTrue Oneday and Bausch + Lomb Ultra, as well as successful performances of newer products, such as Lumify and Thermage. Papa is also optimistic about their newest  dermatology product Duobrii.

 

Related Ticker: BHC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


BHC in +5.53% Uptrend, rising for three consecutive days on November 09, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BHC advanced for three days, in 212 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

BHC moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BHC crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

The Aroon Indicator entered an Uptrend today. In 113 of 155 cases where BHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Bearish Trend Analysis

The 10-day RSI Indicator for BHC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 27 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

BHC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.727) is normal, around the industry mean (6.379). P/E Ratio (-2.782) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.011) is also within normal values, averaging (2.202). BHC has a moderately high Dividend Yield (0.489) as compared to the industry average of (0.062). P/S Ratio (0.197) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. BHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 0%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 10%. XERS experienced the highest price growth at 53%, while AKAN experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 10%. For the same stocks of the Industry, the average monthly volume growth was 21% and the average quarterly volume growth was 16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 55
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 3 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry PharmaceuticalsGeneric

Industry
Pharmaceuticals Other
Address
2150 St Elzear Boulvard West
Phone
+1 514 744-6792
Employees
20300
Web
https://www.bauschhealth.com
Interact to see
Advertisement
AtlasClear Holdings (ATCH) shares fell roughly 25.5% over the last 30 days, declining from $0.1881 on October 2 to $0.1401 on October 30. The pullback extended a longer downtrend that has kept the stock trading well below the $1.00 NYSE American minimum, keeping continued listing-compliance risk in focus.
The central target of $1,620 is the arithmetic mean of verified, current analyst price targets, rounded to a clean level; it is not a single firm's forecast or a guarantee. At a recent price of about $690 , reaching $1,620 would require a gain of roughly 135% , a very large move by any standard.
NVDA fell -2.10% to $216.66 during regular trading, down from a prior close of $221.30. Primary catalyst: hotter-than-expected September CPI data reignited Fed rate-hike fears, raising borrowing costs for AI infrastructure buildouts.
XRPN fell -9.70% in early regular-session trading on Tuesday, sliding from Monday's $10.41 close to $9.40. The decline follows a November 9 SEC prospectus disclosing a committed equity facility with Cantor to sell up to 5.2 million new Class A shares at 97% of the volume-weighted average price, implying up to roughly 16.7% potential dilution.
The $1.14 central target is not an analyst consensus; it is the all-cash merger consideration in GoPro, Inc. (GPRO) 's pending deal with Starman Optical, agreed in September 2026. With the stock trading near $0.88, reaching $1.14 would require a move of roughly 29.5%.